Where is Hypera located?

Hypera is headquartered in Brazil.

Where does Hypera rank among its competitors?

Hypera ranks 82nd amongst 4383 active competitors, of which 124 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Ipsen, which secured $618K in Dec, 2023.

Who are the top competitors of Hypera?

Hypera's top competitors include Abbott, WuXi AppTec and ANI Pharmaceuticals. Among them, Ipsen secured the most recent funding round in December, 2023.

Hypera - 2026 Company Profile & Competitors

Company Details

Manufacturer of prescription and over-the-counter pharmaceuticals, including generic medications, dermocosmetics, and nutritional supplements. It operates across various segments of the pharmaceutical sector, offering a diversified portfolio of products. The company invests in innovation and sustainable growth to improve people's health and well-being. Its product lines cater to both individual consumers and institutional clients such as clinics and hospitals.

Key Metrics

Location

Brazil

Stage

Public

Ranked

82^nd among 4383 active competitors

Similar Companies

Abbott & 3570 more

Exit Details

Public

View Hypera's full profile

Hypera got listed on Apr 18, 2008.

Click here to take a look at Hypera's IPO in detail

Hypera has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Hypera include Abbott, WuXi AppTec and ANI Pharmaceuticals. Here is the list of Top 10 competitors of Hypera, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abbott 1888, Libertyville (United States), Public	Developer of medical devices, generic pharmaceuticals, and nutrition products	-	MSN Laboratories, Digital Pharma Lab & 12 others	80/100
2nd	WuXi AppTec 2000, Shanghai (China), Public	Provider of CRO and CDMO services	$40M	Synergis Capital, HongShan & 27 others	79/100
3rd	ANI Pharmaceuticals 1996, Baudette (United States), Public	Manufacturer of pharmaceutical products, including extended-release capsules and immediate-release tablets	-	JPMorgan Chase, Ampersand Capital & 4 others	64/100
4th	EVERSANA 2014, Milwaukee (United States), Funding Raised	Provider of consulting services for drug pricing access, reimbursement, and regulatory support	-	North Sky Capital, ACE & Company & 2 others	63/100
5th	Ipsen 1929, Paris (France), Public	Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes	-	Digital Pharma Lab, Qualium Investissement ... & 2 others	63/100
6th	Neolife 1958, Fremont (United States), Unfunded	Provider of whole food nutritional supplements	-	-	63/100
7th	Zuellig Pharma 1992, Singapore (Singapore), Funding Raised	Provider of clinical research, quality management, logistics, and clinical trial supply services	-	Temasek	61/100
8th	Eurofins Scientific 1987, Luxembourg (Luxembourg), Public	Provider of laboratory testing services and CRO contract research services	-	CDPQ, Holland Capital & 1 others	61/100
9th	Roquette 1933, Lestrem (France), Funding Raised	CDMO focused on manufacturing of plant based pharma, nutraceuticals, cosmetics, and other products	-	Europa	60/100
10th	Precision Medicine Group 2012, Bethesda (United States), Late Stage	Provider of clinical research, development, and commercialization services for life sciences	$532M	TPG, Oak Investment Partners & 7 others	60/100
82nd	Hypera Brazil, Public	Manufacturer of prescription and over-the-counter pharmaceuticals	-	-	44/100